UNLIMITED TURBO LONG - NOVO-NORDISK B | Delayed Deutsche Boerse AG 06:50:59 03/06/2024 pm IST | ||
| 12.31 EUR | -1.99% |
|
| 1 month | +5.19% | ||
| 3 months | +29.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 12.31 | -1.99% |
| 31/24/31 | 12.56 | +1.45% |
| 30/24/30 | 12.38 | +2.74% |
| 29/24/29 | 12.05 | -0.99% |
| 28/24/28 | 12.17 | -1.54% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 06:50 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PE8GAV |
| ISIN | DE000PE8GAV2 |
| Date issued | 31/01/2023 |
| Strike | 466.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.87 € |
|---|---|
| Lowest since issue | 0.72 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
